|keynote 028 cervical cancer||1.83||0.2||8573||80|
KEYNOTE-028 is an open-label, phase Ib multicohort (20 cohorts) study that explored the safety and efficacy of pembrolizumab in patients with PD-L1–positive tumors. Here, we report the safety, efficacy, and biomarker results from the SCLC cohort of KEYNOTE-028.What is the keynote-028 trial?
Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced cervical cancer. …What is the DOI of JCO 2019 4079?
DOI: 10.1200/JCO.2019.37.15_suppl.4079 Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 4079-4079. Published online May 26, 2019.What is the average follow-up time for kn158 and kn028?
Results: Median (range) follow-up was 7.5 (0.6–29.5) mo in the 104 pts from KN158 and 6.5 (0.6–33.1) mo in the 24 pts from KN028 with BTC. All pts in KN028 and 61 in KN158 had PD-L1–positive tumors. No pt had MSI-H tumors (not assessed in KN028).